STOCK TITAN

Halozyme Thrp - HALO STOCK NEWS

Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.

Halozyme Therapeutics, Inc. (HALO) delivers innovative drug delivery solutions through its proprietary ENHANZE® technology, transforming subcutaneous administration of biologics. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.

Access timely press releases covering earnings reports, ENHANZE® licensing agreements, and oncology pipeline advancements. Our curated collection features updates on FDA submissions, collaboration expansions with global pharmaceutical leaders, and technology applications across autoimmune disorders and cancer treatments.

Key updates include partnership announcements with industry leaders, clinical trial progress for subcutaneous therapies, and financial performance insights. The resource serves investors tracking royalty revenue models and analysts monitoring competitive positioning in biopharmaceutical delivery systems.

Bookmark this page for direct access to verified corporate communications and objective reporting on Halozyme's mission to enhance treatment experiences through advanced drug delivery platforms. Regularly updated to reflect the company's latest achievements in patient-centric biotechnology innovation.

Rhea-AI Summary
Bristol Myers Squibb (BMS) reports positive results from Phase 3 trial of subcutaneous nivolumab in renal cell carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary
Halozyme presents positive results of a clinical study demonstrating successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
partnership clinical trial
-
Rhea-AI Summary
Halozyme announces positive results of a clinical study demonstrating successful subcutaneous administration of a biologic co-formulated with ENHANZE® in 30 seconds
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
Rhea-AI Summary
Halozyme CEO to present at investor conferences: Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) reported a 45% YOY increase in revenue to $221.0 million, with GAAP diluted EPS of $0.56 and Non-GAAP diluted EPS of $0.741. Royalty revenue increased 31% YOY to a record $111.7 million. The company raised 2023 Non-GAAP diluted EPS guidance to $2.65-$2.75 and updated revenue guidance to $825-$845 million, representing 25-28% YOY growth, and EBITDA guidance to $420-$440 million, representing >30% YOY growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
-
Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, with a conference call to discuss the results. The live webcast and replay of the conference call will be available through the 'Investors' section of Halozyme's corporate website at www.halozyme.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings
Rhea-AI Summary
Halozyme Therapeutics announces positive topline data from the ADHERE study for VYVGART Hytrulo in adults with CIDP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
Halozyme Thrp

Nasdaq:HALO

HALO Rankings

HALO Stock Data

7.32B
122.11M
1.16%
102.39%
7.92%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO